Min Lu

Min Lu

Company: Morphic Therapeutics

Job title: Executive Director & Head of Fibrosis


Targeting TGF-β Selectively to Achieve Antifibrotic Efficacy without Safety Concerns 11:00 am

• Outlining roles of TGFβ1, 2 and 3, as master regulators of fibrosis • Exploring pleiotropic effects and challenges in development, immune homeostasis, and cell cycle regulation • Selective and local inhibition of TGFβ activation may show therapeutic potential for fibrosis indicationsRead more

day: Day Two

A Hanson Wade Group Company

© Copyright 2024 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.